Literature DB >> 15208528

The role of interferon therapy in hepatitis B.

W Graham E Cooksley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15208528      PMCID： PMC1140699     

Source DB:  PubMed          Journal:  MedGenMed        ISSN： 1531-0132


× No keyword cloud information.
  17 in total

Review 1.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

Authors: 
Journal:  J Hepatol       Date:  2003-04       Impact factor: 25.083

Review 2.  Interferon-alpha for HBeAg-positive chronic hepatitis B.

Authors:  Antonio Craxì; Danilo Di Bona; Calogero Cammà
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

3.  Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).

Authors:  H L Janssen; G Gerken; V Carreño; P Marcellin; N V Naoumov; A Craxi; H Ring-Larsen; G Kitis; J van Hattum; R A de Vries; P P Michielsen; F J ten Kate; W C Hop; R A Heijtink; P Honkoop; S W Schalm
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

4.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

Authors:  S W Schalm; J Heathcote; J Cianciara; G Farrell; M Sherman; B Willems; A Dhillon; A Moorat; J Barber; D F Gray
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

5.  Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon.

Authors:  F Oliveri; T Santantonio; G Bellati; P Colombatto; G C Mels; L Carriero; G Dastoli; G Pastore; G Ideo; F Bonino; M R Brunetto
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

6.  A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.

Authors:  P Lampertico; E Del Ninno; A Manzin; M F Donato; M G Rumi; G Lunghi; A Morabito; M Clementi; M Colombo
Journal:  Hepatology       Date:  1997-12       Impact factor: 17.425

7.  Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

Authors:  D K Wong; A M Cheung; K O'Rourke; C D Naylor; A S Detsky; J Heathcote
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

8.  Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Authors:  W G E Cooksley; T Piratvisuth; S-D Lee; V Mahachai; Y-C Chao; T Tanwandee; A Chutaputti; W Yu Chang; F E Zahm; N Pluck
Journal:  J Viral Hepat       Date:  2003-07       Impact factor: 3.728

9.  Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group.

Authors:  H C Thomas; A S Lok; V Carreño; G Farrell; H Tanno; V Perez; G M Dusheiko; G Cooksley; J C Ryff
Journal:  J Viral Hepat       Date:  1994       Impact factor: 3.728

10.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.

Authors:  C Niederau; T Heintges; S Lange; G Goldmann; C M Niederau; L Mohr; D Häussinger
Journal:  N Engl J Med       Date:  1996-05-30       Impact factor: 91.245
View more
  8 in total

Review 1.  Small Molecules and Antibodies for Zika Therapy.

Authors:  Xuping Xie; Jing Zou; Chao Shan; Pei-Yong Shi
Journal:  J Infect Dis       Date:  2017-12-16       Impact factor: 5.226

2.  Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.

Authors:  Matteo Rossi; Patrik Castiglioni; Mary-Anne Hartley; Remzi Onur Eren; Florence Prével; Chantal Desponds; Daniel T Utzschneider; Dietmar Zehn; Maria G Cusi; F Matthew Kuhlmann; Stephen M Beverley; Catherine Ronet; Nicolas Fasel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

3.  miR-146a negatively regulates NK cell functions via STAT1 signaling.

Authors:  Dongqing Xu; Qiuju Han; Zhaohua Hou; Cai Zhang; Jian Zhang
Journal:  Cell Mol Immunol       Date:  2016-03-21       Impact factor: 11.530

4.  Antiviral Potential of a Novel Compound CW-33 against Enterovirus A71 via Inhibition of Viral 2A Protease.

Authors:  Ching-Ying Wang; An-Cheng Huang; Mann-Jen Hour; Su-Hua Huang; Szu-Hao Kung; Chao-Hsien Chen; I-Chieh Chen; Yuan-Shiun Chang; Jin-Cherng Lien; Cheng-Wen Lin
Journal:  Viruses       Date:  2015-06-17       Impact factor: 5.048

Review 5.  Schlafens Can Put Viruses to Sleep.

Authors:  Eui Tae Kim; Matthew D Weitzman
Journal:  Viruses       Date:  2022-02-21       Impact factor: 5.048

6.  The Arabian camel, Camelus dromedarius interferon epsilon: Functional expression, in vitro refolding, purification and cytotoxicity on breast cancer cell lines.

Authors:  Manal Abdel-Fattah; Hesham Saeed; Lamiaa El-Shennawy; Manal Shalaby; Amira Embaby; Farid Ataya; Hoda Mahmoud; Ahmed Hussein
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

7.  Low-dose interferon-α treatment improves survival and inflammatory responses in a mouse model of fulminant acute respiratory distress syndrome.

Authors:  Daisuke Kudo; Kazuko Uno; Tetsuji Aoyagi; Yukiko Akahori; Keiko Ishii; Emi Kanno; Ryoko Maruyama; Shigeki Kushimoto; Mitsuo Kaku; Kazuyoshi Kawakami
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

Review 8.  Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment.

Authors:  Laith N Al-Eitan; Saif Z Alahmad
Journal:  Rev Med Virol       Date:  2020-11-17       Impact factor: 11.043
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.